Free Trial

Veracyte Q2 2024 Earnings Report

Veracyte logo
$39.18 -1.87 (-4.56%)
As of 04:00 PM Eastern

Veracyte EPS Results

Actual EPS
$0.07
Consensus EPS
-$0.03
Beat/Miss
Beat by +$0.10
One Year Ago EPS
-$0.12

Veracyte Revenue Results

Actual Revenue
$114.43 million
Expected Revenue
$100.27 million
Beat/Miss
Beat by +$14.16 million
YoY Revenue Growth
+26.70%

Veracyte Announcement Details

Quarter
Q2 2024
Time
After Market Closes

VCYT Upcoming Earnings

Veracyte will be holding an earnings conference call on Monday, February 24 at 4:30 PM Eastern. Interested parties can register for or listen to the call.

Conference Call Resources

Veracyte Earnings Headlines

Veracyte, Inc.
Analysts Set Veracyte, Inc. (NASDAQ:VCYT) Price Target at $42.00
Top Picks for Trump’s Pro-Crypto America
10,000% Crypto Opportunities in 2025 27 of the brightest minds in crypto share exclusive intel…
Veracyte to Participate in Upcoming Investor Conferences
Veracyte (NASDAQ:VCYT) Lowered to "Hold" Rating by StockNews.com
See More Veracyte Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Veracyte? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Veracyte and other key companies, straight to your email.

About Veracyte

Veracyte (NASDAQ:VCYT) engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

View Veracyte Profile

More Earnings Resources from MarketBeat